Standard BioTools Charts Path to Enhanced Cash Position With SomaLogic Acquisition on Horizon

MevHunter · 2026-01-12T17:51:08+00:00

Standard BioTools Inc. forecasts a combined revenue of $185 million for 2025, with $56 million projected for Q4. CEO Michael Egholm highlighted a strategic transition, expecting significant cash reserves post-divestiture, enhancing operational and investment flexibility.

MevHunter

2026-01-12 17:51:08

Abstract generation in progress

Life science tools provider Standard BioTools Inc. (LAB) has unveiled its preliminary financial trajectory for the fourth quarter and full year of 2025, signaling momentum heading into 2026. The company anticipates combined revenue reaching approximately $185 million for the full year, with continuing operations contributing roughly $85 million to this total.

For the fourth quarter specifically, Standard BioTools projects combined revenue of about $56 million, of which continuing operations are expected to account for approximately $24 million. The divergence between combined company and continuing operations revenue underscores the company’s ongoing portfolio transformation, an important consideration when analyzing cost of revenue from operations formula and operational efficiency metrics.

CEO Michael Egholm offered an optimistic outlook during the announcement, emphasizing the strategic inflection point ahead. “Looking to 2026, the divestiture of SomaLogic to Illumina is progressing according to schedule, with closure anticipated during the first half of the year,” Egholm stated. He highlighted that upon transaction completion, Standard BioTools will maintain approximately $550 million in cash reserves—a substantial capital buffer positioned to accelerate the transition of the core business toward positive adjusted EBITDA.

This combination of enhanced liquidity and an increasingly efficient operational base creates significant strategic flexibility for capital allocation, whether directed toward research initiatives, market expansion, or shareholder returns. The company plans to deliver comprehensive fourth-quarter and full-year 2025 financial results during the current quarter, providing additional detail on operational performance and forward guidance.

Trading activity reflects investor confidence in the company’s trajectory, with Standard BioTools shares demonstrating positive momentum in recent sessions.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.